Understanding GLT18: A Potential Drug Target and Biomarker (G374378)

Target Name: GALNT18

NCBI ID: G374378

GALNT18

Understanding GLT18: A Potential Drug Target and Biomarker

GALNT18 (GLT18_HUMAN), a gene that encodes for a protein known as GLT18, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and metabolic disorders. Its functions and interactions with other genes have been extensively studied, providing a clear understanding of its role in human biology.

GLT18, a member of the G-protein-coupled receptor (GPCR) family, is a key regulator of cellular processes, including cell adhesion, migration, and survival. It is expressed in various tissues and cells throughout the body and plays a crucial role in the development and maintenance of tissues and organs, as well as in maintaining tissue homeostasis. GLT18 has been implicated in various physiological processes, including the regulation of angiogenesis, tissue repair, and inflammation.

GLT18 is a key regulator of cell-cell adhesion, which is a critical process in the development and maintenance of tissues and organs. During development, GLT18 helps to ensure that cells stick together to form tissues and organs, while during maintenance, it helps to maintain tissue homeostasis by regulating cell-cell interactions. GLT18 has been shown to play a crucial role in the regulation of angiogenesis, the formation of new blood vessels, and the maintenance of blood vessels.

GLT18 is also involved in the regulation of tissue repair and regeneration. During wound healing, GLT18 helps to ensure that cells are able to migrate and differentiate into new tissue, allowing for the formation of new tissues and organs. Additionally, GLT18 has been shown to play a role in the regulation of stem cell proliferation and the maintenance of stem cell self-renewal.

GLT18 is also involved in the regulation of inflammation, which is a crucial immune response that helps to protect the body against infection and disease. GLT18 has been shown to play a role in the regulation of inflammation by controlling the movement of immune cells and the production of pro-inflammatory cytokines.

The potential drug target for GLT18 is its role in cancer, neurodegenerative disorders, and metabolic disorders. GLT18 has been shown to promote the growth and survival of cancer cells, making it a potential target for cancer therapies. Additionally, GLT18 has been implicated in the development and progression of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The regulation of GLT18 has been shown to play a role in the development and progression of these disorders. Finally, GLT18 has also been implicated in the regulation of various metabolic processes, including glucose and lipid metabolism.

In conclusion, GLT18 (GLT18_HUMAN) is a gene that has the potential to be a drug target and biomarker for various diseases. Its functions and interactions with other genes have been extensively studied, providing a clear understanding of its role in human biology. Further research is needed to fully understand the potential therapeutic uses of GLT18 and to develop effective treatments for various diseases.

Protein Name: Polypeptide N-acetylgalactosaminyltransferase 18

Functions: Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine (GalNAc) residue from UDP-GalNAc to a serine or threonine residue on the protein receptor

The "GALNT18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GALNT18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets